Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg keeps Kingfisher at 'hold' as mixed conditions continue

(Sharecast News) - Berenberg has reiterated a 'hold' rating on Kingfisher ahead of the DIY retailer's third-quarter update next month, highlighting concerns about profit margins amid a mixed market backdrop. While home-related retail sales trends look supportive in the UK - which accounts for more than half of Kingfisher's revenues - trading across France and Poland has been "more challenging" in recent months, Berenberg said.

The broker has pencilled in 2.2% like-for-like sales growth in the UK for the three months to 31 October, countered by a 4.5% decline in France and a 2.0% drop in Poland. As a result, group LFL sales are expected to have fallen by 0.3% over last year.

Berenberg has lowered its profit estimates, due to a "slightly less enthusiastic approach to the margin trajectory", dampened by tough conditions in France and Poland, along with rising employee cost pressures. However, the broker still estimates that the full-year adjusted pre-tax profit will be £548m, up 4% over last year at above the top end of company guidance.

In addition, Berenberg said that while Kingfisher's recent launches of ecommerce marketplaces across its major markets could be positive for profitability, "margins remain low in absolute terms, along with sales densities and ROIC".

The shares trade at 11 times earnings, which the broker said "looks undemanding". Nevertheless, the 331p target price for the stock suggests very little upside to Friday morning's price of 311p, down 0.7% on the day.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.